[Intraperitoneal chemotherapy for gastric carcinoma combined with peritoneal dissemination by intraperitoneal catheter with a subcutaneous reservoir].
Peritoneal dissemination is one of the leading causes of death among the gastric cancer patients. To improve the prognosis of these patients, we employed intraperitoneal repeated chemotherapy by intraperitoneal catheter with a reservoir implanted subcutaneously at the initial operation in 10 patients with peritoneal dissemination. At the initial operation, CDDP (50 or 100mg body), diluted in warm saline (total, 1,000ml), was administered intraperitoneally. Three to four weeks later, 50 to 70 mg/m2 of CDDP with saline was injected via the device, followed by 5-days of continuous intravenous administration of 5-FU (250 to 350 mg/m2). This therapy was repeated at 3- to 4-week intervals. One to seven cycles were used in this study. Among the highly disseminated cases, four of eight patients were alive more than one year, two died of cancer within four months and 2 are under treatment. Therapeutic toxicity was manifested as anorexia, nausea and vomiting. All the laboratory data were better than Grade 2 level. Thus, intraperitoneal repeated chemotherapy by CDDP is a safe and effective treatment for patients with peritoneal dissemination.
Kurita
A
A
Dept. of Surgery, Shikoku Cancer Center Hospital.
Takashima
S
S
Takayama
T
T
Doihara
H
H
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D015918:Infusion Pumps, Implantable; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D011379:Prognosis; D013274:Stomach Neoplasms / Q000473:pathology*
D002945:Cisplatin; D005472:Fluorouracil